การภาคสนาม มีความไวกว่าตัวเลือกในปัจจุบั นถึง 80,000 ครั้ง
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — ในขณะที่ชุมชนโลกมารวมตัวกั
บริษัท Meridian Bioscience, Inc. ใน Cincinnati, Ohio (NASDAQ:VIVO) ได้พัฒนา illumigene® Malaria ขึ้นซึ่งเป็นการทดสอบที่ใช้
“illumigene Malaria มีศักยภาพในการเปลี่
illumigene Malaria ได้รับรางวัลที่หนึ่งสำหรับนวั
เมื่อรวบรวมรายงานแล้ว เกือบร้อยละ 43 ของกรณีโรคมาลาเรียที่จดทะเบี
ความพร้อมใช้งานของ illumigene Malaria ซึ่งเป็นการทดสอบที่ใช้ได้ในห้
illumigene Malaria จะมีจัดจำหน่ายในยุโรป ตะวันออกกลาง และแอฟริกาโดยบริษัท Meridian Bioscience Europe และในตลาดต่างประเทศเพิ่มเติ
1 – ข่าวประชาสัมพันธ์ของ Meridian “การทดสอบมาเลเรียใหม่ illumigene Malaria ได้กำหนดมาตรฐานใหม่ในการวินิ
2 – องค์การอนามัยโลก: 10 ข้อเท็จจริงเกี่ยวกับโรคมาลาเรี
3 – เช่นเดียวกับข้อ 2
4 – เช่นเดียวกับข้อ 2
5 – เช่นเดียวกับข้อ 2
6 – องค์การอนามัยโลก, กลยุทธ์
เกี่ยวกับบริษัท Meridian Bioscience, illumigene Malaria และเทคโนโลยี LAMP
- illumigene Malaria เป็นการตรวจวินิจฉัยโรคมาลาเรี
ยที่ได้รับการพัฒนาโดยบริษัท Meridian Bioscience โดยเป็นการทดสอบระดับโมเลกุลที่ ใช้เทคโนโลยี Isothermal Loop-Mediate Amplification (LAMP) เพื่อขยาย DNA และตรวจจับการปรากฏตัวของปรสิ ตมาลาเรีย
- LAMP (Loop Mediated Isothermal Amplification) คือเทคโนโลยีการตรวจจับระดั
บโมเลกุลที่กำหนดเป้าหมาย DNA และใช้สารรีเอเจนต์ที่ตรวจวั ดได้และมีอยู่ในตัว แตกต่างจากการทดสอบ PCR ในปัจจุบัน LAMP ไม่จำเป็นต้องมีรอบอุณหภูมิ แต่สามารถทำการอบ ตรวจจับ และรายงานที่อุณหภูมิเดียวเพื่ อให้ได้ผลลัพธ์ที่รวดเร็วขึ้น ชุดทดสอบ illumigene สามารถเก็บไว้ภายใต้ สภาพแวดล้อมที่มีอยู่ ในขณะที่วิธีการโมเลกุลในปัจจุ บันจำเป็นต้องเก็บในความเย็น
- เทคโนโลยี illumigene ไม่ยุ่งยาก ถูกต้อง และใช้งานได้ง่าย ซึ่งหมายความว่าไม่จำเป็นต้องมี
ผู้เชี่ยวชาญด้านเทคนิคเพื่ อทำการทดสอบ จะได้ผลลัพธ์ภายในเวลาไม่ถึงหนึ่ งชั่วโมง
- การทดสอบ illumigene ซึ่งใช้เทคโนโลยี LAMP เป็นพื้นฐานพร้อมสำหรับวินิจฉั
ยโรคติดเชื้อ ได้แก่ C. difficile โรคไอกรน และ ไวรัสเริม ซึ่งพิสูจน์แล้วว่ามีความแม่ นยำสูง
- การทดสอบ illumigene ได้รับการอนุมัติ
และสามารถใช้ในโรคอื่นๆ มานานกว่า 5 ปีแล้ว
- ข้อดีของ illumigene Malaria ได้รวบรวมไว้ที่ www.molecularendsmalaria.com.
เกี่ยวกับบริษัท Meridian Bioscience, Inc
กลงทุน กรุณาติดต่อ: 513-271-3700 John A. Kraeutler ประธานเจ้าหน้าที่บริหาร สำหรับข้อซักถามอื่นๆ กรุณาติดต่อ: 513-403-7222 Joe Shields
- op-line results are expected in the third quarter of 2017
- The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D)
- IBS is one of the most common gastrointestinal disorders; it is estimated that at least 30 million Americans suffer from IBS, of which over 40% are cases of IBS-D
- If approved, BEKINDA® 12 mg has the potential to be a preferred once-daily treatment for a broad segment of patients suffering from IBS-D, targeting a U.S. potential market estimated to exceed $1 billion by 2022
- Top-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017
- RedHill will host an R&D Day and live webcast on BEKINDA® on Thursday, April 27, 2017 in NYC, discussing the product, indications, potential markets and the ongoing Phase III and II studies for acute gastroenteritis and IBS-D, respectively
TEL-AVIV, Israel, April 24, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced enrollment of the last patient in the Phase II study with BEKINDA® (RHB-102)1 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal indications.
The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® 12 mg in adults over the age of 18 with IBS-D. The study enrolled 127 subjects in 16 U.S. clinical sites. Top-line results are expected in the third quarter of 2017.
Subjects enrolled in the Phase II IBS-D study were randomized 60:40 to receive either BEKINDA® 12 mg or a placebo, once daily, for a period of eight weeks. The primary endpoint for the study is the proportion of patients in each treatment group with response in stool consistency as compared to baseline, per FDA guidance definition. Secondary endpoints include the proportion of patients in each treatment group who are pain responders and the proportion of patients in each treatment group who are responders to the combined endpoints of stool consistency and pain, per FDA guidance definition.
IBS is one of the most common gastrointestinal disorders2. It is estimated that at least 30 million Americans suffer from IBS3, of which over 40% are cases of IBS-D4. The U.S. potential market for IBS-D treatments is estimated to exceed $1 billion by 20225.
5-HT3 antagonists such as ondansetron, the active pharmaceutical ingredient in BEKINDA®, have been shown to slow intestinal transit time in humans6. Alosetron (Lotronex®), a 5-HT3 antagonist of the same class of drugs as ondansetron, has been approved by the FDA for the treatment of women with severe chronic IBS-D, but is under a restricted prescribing (REMS) program due to potential severe side effects7. Ondansetron, approved by the FDA as an oncology support antiemetic, has demonstrated activity in IBS-D in preliminary studies8 and, in light of its safety profile, RedHill believes that BEKINDA®, if approved, has the potential to be a preferred once-daily treatment for a broad segment of patients suffering from IBS-D.
Top-line results from the Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017. In February 2017, RedHill announced that the last patient had completed the treatment course and observation period in the randomized, double-blind, placebo-controlled GUARD study, which treated 320 adults and children over the age of 12 in 29 U.S. clinical sites.
The Phase II study and the Phase III GUARD study with BEKINDA® are registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies.
About BEKINDA® (RHB-102):
BEKINDA® is a proprietary, bimodal extended-release (24 hours) oral pill formulation of ondansetron, covered by several issued and pending patents. A Phase III clinical study of BEKINDA® 24 mg formulation for acute gastroenteritis and gastritis (the GUARD study) is ongoing in the U.S., with patient treatment course and observation period completed and top-line results expected in the second quarter of 2017. A Phase II study with BEKINDA® 12 mg formulation is ongoing in the U.S. for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), with patient enrollment completed and top-line results expected in the third quarter of 2017.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, as well as an exclusive license agreement with Entera Health for EnteraGam®, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill’s clinical-stage pipeline includes: (i) RHB-105 – an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 – an oral combination therapy for the treatment of Crohn’s disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and QIDP status for nontuberculous mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) – a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 – an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) – a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON – a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors and (vii) RIZAPORT® (RHB-103) – an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP). More information about the Company is available at: www.redhillbio.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully market Donnatal® and EnteraGam®, (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xiii) competitive companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.
1 BEKINDA® is an investigational new drug, not available for commercial distribution.
2 GlobalData PharmaPoint: Irritable Bowel Syndrome – Global Drug Forecast and Market Analysis to 2023.
3 Lovell RM, Ford AC, Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol (2012), 10(7)712-721; Saito YA et al, The epidemiology of irritable bowel syndrome in North America: a systemic review, Am J Gastroenterol (2002), 97(8): 1910-5.
4 GlobalData PharmaPoint: Irritable Bowel Syndrome – Global Drug Forecast and Market Analysis to 2023.
5 EvaluatePharma – Irritable bowel syndrome Indication Profile.
6 Garsed K. et al, A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut (2014), 63(10): 1617-25.
7 www.fda.gov, post market drug safety information for patients and providers.
8 Steadman CJ et al, Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study, Mayo Clin Proc (1992), 67(8):732-8; Clayton NM et al, The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat, Neurogastroenterol (1999), 11: 207-217; Garsed K. et al, A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut (2014), 63(10): 1617-25.
Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 firstname.lastname@example.org IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927 Mnanus@troutgroup.com
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) — As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.
Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal.
“illumigene Malaria has the potential to change current practices. Faster and more accurate diagnosis is vital in the fight against malaria,” said Professor Daouda Ndiaye, Department of Parasitology-Mycology, Cheikh Anta Diop University. “Earlier diagnosis enables the correct treatment to be prescribed, which leads to better clinical outcomes for the person with malaria and keeps malaria treatments for the right people. And because detecting the malaria parasite in people with a low parasite count has proven difficult, a robust, sensitive and field laboratory-deployable diagnostic tool is needed to track the malaria reservoir in pre-elimination regions. illumigene Malaria shows this capacity.”
illumigene Malaria was awarded first place for innovation in emergency treatment and point-of-care testing at the prestigious Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris, and is CE marked for sale in Europe.
Despite a 60% decline in malaria deaths since 2000 due to better prevention and increased control measures, malaria is still one of the top three killers of children worldwide, claiming one life every minute of every day. (1) According to the latest data from the World Health Organization, nearly half of the world’s population is at risk of malaria (2). In 2015, there were roughly 212 million malaria cases and an estimated 429,000 malaria deaths (3). Also that year, Sub-Saharan Africa was home to 90% of malaria cases and 92% of malaria deaths (4). More than two-thirds (70%) of all malaria deaths occur in children under the age of five (5).
While malaria is preventable and treatable (6), proper diagnosis is critical. Molecular testing has proven to be more effective than current options in detecting the malaria parasite at very low levels, known as “loads.” Identifying low-load individuals has the dual benefit of ensuring they receive treatment and preventing the spread of the disease to others.
“People can be carriers of malaria without showing any symptoms, and detecting these asymptomatic individuals can be challenging,” said Slava Elagin, Executive Vice President, Research & Development at Meridian Bioscience. “If testing doesn’t identify them, eliminating malaria is impossible because these individuals can spread the disease to others.”
That scenario is playing out in the fact that malaria is no longer only a disease of sub-Saharan Africa and southern Asia. Increasing numbers of people emigrating from countries where malaria is endemic have resulted in a higher incidence in Europe and the Middle East. The proportion of imported malaria cases has increased during the last few years from 14% to 86% in more recent studies. On pooling the reports, nearly 43% of malaria cases registered in key European centers occurred in non-nationals. The rates of malaria are much higher in settled immigrants who travel to visit friends and relatives in their country of origin. They can account for up to 70% of the cases in several reports and this increase highlights the need for better diagnostic tools in both non-endemic and endemic countries.
While not a new concept, molecular testing has traditionally been a complex process requiring fully-equipped laboratories and highly trained testing personnel. The breakthrough of illumigene Malaria by Meridian Bioscience is that it can be deployed in the field laboratory, where malarial infection is the highest and low load detection most challenging to diagnose and treat. illumigene Malaria is user-friendly, doesn’t require special training or capital investment, yields results in under one hour and the testing materials can be stored at room temperature.
“This is a major step forward in the fight to bring better care to those infected with malaria and to stop its spread,” said John A. Kraeutler, Chief Executive Officer and Chairman of the Board of Meridian Bioscience.
The availability of the field laboratory-deployable and user-friendly, illumigene Malaria, will enhance rather than replace existing testing protocols. It will join rapid diagnostic tests (RDTs) and microscopy to create a web of detection protocols that will help direct treatment where it is needed most.
“Malaria is a devastating disease and we are proud to work with all the talented and dedicated individuals around the world in the fight to eliminate it,” said Kraeutler.
illumigene Malaria will be distributed in the European, Middle Eastern and African regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network. It is the tenth assay now available on our illumigene platform that is in use in nearly 1,500 institutions around the world.
1 – Meridian news release, “New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis”, 1.26.16
2 – World Health Organization: 10 facts on malaria (http://www.who.int/features/
3 – ibid
4 – ibid
5 – ibid
6 – The World Health Organization, Global Technical Strategy for Malaria: 2016-2030
About Meridian Bioscience, illumigene Malaria & LAMP Technology
- illumigene Malaria is a diagnostic test for malaria developed by Meridian Bioscience. It is a molecular test that uses Loop-Mediated Isothermal Amplification (LAMP) technology to amplify DNA and detect the presence of the Malaria parasite.
- LAMP (Loop Mediated Isothermal Amplification) is Molecular detection technology which targets DNA and uses premeasured and self-contained reagents. Unlike current PCR testing, it does not require temperature cycling. LAMP incubates, detects and reports at a single temperature, allowing for faster results. illumigene testing kits can be stored under ambient conditions, while current molecular methods require cold storage.
- illumigene technology is simple, accurate and easy to use which means that no specialist technical expertise is needed to perform the test. Results are available in under an hour.
- LAMP-based illumigene tests are already used to diagnose infectious diseases including C. difficile, whooping cough and Herpes Simplex Virus, where they have proved highly accurate.
- illumigene tests have been approved and used in other diseases for over 5 years.
- The benefits of illumigene Malaria are highlighted on the microsite: www.molecularendsmalaria.com.
About Meridian Bioscience, Inc
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
For Investor Relations, contact: 513-271-3700 John A. Kraeutler, Chief Executive Officer For all other inquiries, contact: 513-403-7222 Joe Shields
ASKER, Norway, April 24, 2017 (GLOBE NEWSWIRE) — TGS announces new multi-client acquisition project, Crean 3D on the Irish Atlantic Margin.
A photo accompanying this announcement is available at http://www.globenewswire.com/
Crean 3D (CRN 3D) is a multi-client survey of more than 5,400 km2 located in the South Porcupine Basin between the Porcupine High and the Irish Mainland Platform. Multi-level targets exist, such as Paleocene and Mesozoic channel/fan systems overlying tilted fault blocks. Exploration success on the Newfoundland Labrador conjugate margin coupled with historical exploration in Atlantic Ireland has resulted in significant acreage being licensed. TGS will acquire new 3D data to provide the higher spatial resolution required to delineate multiple plays at multiple levels. Acquisition is expected to commence in June 2017. Data processing will be performed by TGS using its Clari-FiTM broadband technology.
“Crean 3D will expand TGS’ modern 3D coverage in the underexplored Porcupine Basin. With the successful Atlantic Ireland license round in 2016, we see that activity across the Porcupine Basin is continuing to increase, creating exciting new opportunities. The Crean 3D survey further adds to our Atlantic Margins library which also includes data and new acquisition in the Norwegian Sea, North West Africa and Newfoundland Labrador,” commented Kristian Johansen, CEO for TGS.
This survey is supported by industry funding.
TGS-NOPEC Geophysical Company (TGS) provides multi-client geoscience data to oil and gas Exploration and Production companies worldwide. In addition to extensive global geophysical and geological data libraries that include multi-client seismic data, magnetic and gravity data, digital well logs, production data and directional surveys, TGS also offers advanced processing and imaging services, interpretation products, and data integration solutions.
For more information visit TGS online at www.tgs.com.
Forward-looking statements and contact information
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS’ reliance on a cyclical industry and principle customers, TGS’ ability to continue to expand markets for licensing of data, and TGS’ ability to acquire and process data products at costs commensurate with profitability. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.
TGS-NOPEC Geophysical Company ASA is listed on the Oslo Stock Exchange (OSLO:TGS).
TGS sponsored American Depositary Shares trade on the U.S. over-the-counter market under the symbol “TGSGY”.
For additional information about this press release please contact:
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Sven Børre Larsen Chief Financial Officer Tel: +47 90 94 36 73 Email: email@example.com Will Ashby VP HR & Communication Tel: +1 713 860 2184 Email: firstname.lastname@example.org
Police are hunting for a Chulalongkorn University's former professor who operated what was suspected to be a Ponzi scheme and escaped with about one billion baht in investments of his investors.
Pol Lt-Gen Thitirach Nongharnpitak, commissioner of Central Investigation Bureau, said Sunday that a warrant had been issued by the court for the arrest of Associate Professor Sawat Sangbangpla, former chairman of Chulalongkorn University's savings cooperatives, after complaints were lodged to the police by hundreds of people who claimed they were cheated of their investment money by the professor.
The victims placed their investments, amounting from one million baht up to 70 million baht, with the professor who reportedly invested in lottery quota purchases, in exchange for a monthly return for one percent of their investments.
They claimed that they received some monthly returns from the professor who eventually went missing with their investments.
Source: Thai Public Broadcasting Service (Thai PBS)
Rescue workers on Saturday caught a two-metre cobra from the toilet seat in a house in Pan Thong district of Chon Buri.
The rescue workers from a foundation were alerted by Ms Tanyarat Youngsook who said she went into the toilet in her parents' home in Tambon Pan Thong and found water in the toilet murky.
So she flushed the toilet with water and, to her shock, a snake emerged, prompting her to scream for help as she sprinted out of the toilet.
Rescue workers tried for about half an hour before they managed to catch the snake which was identified as a cobra, about two metres long.
It was not known how the cobra got into the toilet seat, but it was later released into the wilderness.
Source: Thai Public Broadcasting Service (Thai PBS)